CCR 20 Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma—The Progress and the Limitations
نویسندگان
چکیده
Vredenburgh and colleagues conducted the first phase II study of bevacizumab plus irinotecan in recurrent malignant glioma, confirming the safety and efficacy of bevacizumab. This study, which was published in the February 15, 2007, issue of Clinical Cancer Research, was a stepping stone for subsequent research, leading to regulatory approval of bevacizumab for recurrent glioblastoma. Clin Cancer Res; 21(19); 4248–50. 2015 AACR. See related article by Vredenburgh et al., Clin Cancer Res 2007; 13(4) February 15, 2007;1253–9
منابع مشابه
CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.
Vredenburgh and colleagues conducted the first phase II study of bevacizumab plus irinotecan in recurrent malignant glioma, confirming the safety and efficacy of bevacizumab. This study, which was published in the February 15, 2007, issue of Clinical Cancer Research, was a stepping stone for subsequent research, leading to regulatory approval of bevacizumab for recurrent glioblastoma.
متن کاملInvestigating the Commentators’ Thought Process on Commentary of the Verse “Yet ye will not, unless Allah willeth”
The verse “Yet ye will not, unless Allah willeth” has been discussed and investigated in different interpretative and theological periods. For some commentators and theologians this verse points to “fatalism” and for some others it entails “human free will under the auspices of the Devine Will”. Semantic analysis of the verse with an emphasis on the commentaries reveals that the commentators’ i...
متن کاملComparison of Intravitreal Injection of Bevacizumab and Triamcinolone Acetonide in the Treatment of Uveitic Macular Edema
Background: Cystoid Macular Edema (CME) is one of the most common and sight threatening complications of uveitis. Intravitreal injection of corticosteroids and anti-VEGF antibody are two routine options for treatment. Objective: To compare the effects of intravitreal injections of Bevacizumab and Triamcinolone Acetonide for the treatment of persistent macular edema in non-infectious uveitis. Me...
متن کاملAngiogenesis inhibitors in tackling recurrent glioblastoma.
INTRODUCTION Despite aggressive multimodality treatment of glioblastoma, outcome remains poor and patients mostly die of local recurrences. Besides reoperation and occasionally reirradiation, systemic treatment of recurrent glioblastoma consists of alkylating chemotherapy (lomustine, temozolomide), bevacizumab and combinations thereof. Unfortunately, antiangiogenic agents failed to improve surv...
متن کاملCCR 20th anniversary commentary: In the beginning, there was PS-341.
Proteasome inhibitors have a 20-year history in cancer therapy. The first proteasome inhibitor, bortezomib, a breakthrough treatment for multiple myeloma, moved rapidly through development from the bench in 1994 to first FDA approval in 2003. Clinical Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezomib, carfilzomib, and the oral prot...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2015